1. Home
  2. SCNX vs CTXR Comparison

SCNX vs CTXR Comparison

Compare SCNX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scienture Holdings Inc.

SCNX

Scienture Holdings Inc.

N/A

Current Price

$0.39

Market Cap

18.4M

Sector

Health Care

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

N/A

Current Price

$0.85

Market Cap

16.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCNX
CTXR
Founded
2010
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
16.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
SCNX
CTXR
Price
$0.39
$0.85
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$1.50
$6.00
AVG Volume (30 Days)
266.6K
585.2K
Earning Date
01-01-0001
06-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$347.88
N/A
Revenue Next Year
$744.44
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.63
52 Week High
$3.17
$2.38

Technical Indicators

Market Signals
Indicator
SCNX
CTXR
Relative Strength Index (RSI) 39.14 55.02
Support Level $0.37 $0.66
Resistance Level $0.47 $0.97
Average True Range (ATR) 0.03 0.07
MACD 0.00 0.02
Stochastic Oscillator 17.42 58.09

Price Performance

Historical Comparison
SCNX
CTXR

About SCNX Scienture Holdings Inc.

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: